T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination
Chen J-L. et al, (2025), Nature Communications, 16
The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis.
Woolley SD. et al, (2025), The Journal of antimicrobial chemotherapy, 80, 1455 - 1457
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.
Singh K. et al, (2024), The Journal of infectious diseases, 230, 624 - 634
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.
Mccabe L. et al, (2024), AIDS (London, England)
Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
Michael BD. et al, (2024), Nature Communications, 15
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Liew F. et al, (2024), Nature Immunology, 25, 607 - 621
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.
White P. et al, (2023), Journal of neurology, neurosurgery, and psychiatry
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
Vanderven HA. et al, (2023), JCI Insight
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.
McCann N. et al, (2023), BMJ Open, 13
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Siggins MK. et al, (2023), Immunology, 168, 473 - 492
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Goldswain H. et al, (2023), Genome biology, 24
Malaria patient spectrum representation in therapeutic clinical trials of uncomplicated malaria: a scoping review of the literature.
Arena L. et al, (2023), Malaria journal, 22
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Mentzer AJ. et al, (2023), Nature Medicine, 29, 147 - 157
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402
Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study.
Vink E. et al, (2022), Open forum infectious diseases, 9
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19
Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Keeling MJ. et al, (2022), Statistical Methods in Medical Research, 31, 1716 - 1737